Anterix Announces Executive Leadership Changes to Power Next Phase of Growth

(NASDAQ:ATEX), WOODLAND PARK, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) — Anterix (NASDAQ: ATEX), the leading provider of private wireless broadband spectrum for utilities today announced changes in the executive leadership team that further position the company to deliver transformative connectivity solutions to utilities and a growing set of critical infrastructure sectors. Anterix's new senior leaders […]

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

(NASDAQ:INKT), Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD) Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

(NASDAQ:CYTK), Long-Term Data from FOREST-HCM in Non-Obstructive HCM and Results from Prespecified Analysis of MAPLE-HCM to be Presented in Late-Breaking Clinical Research Session SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Clinical Research presentations and one poster presentation, at the

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

(NasdaqGM:LPAA), HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

(NasdaqGM:LPAA), HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA(R) (arimoclomol) and OLPRUVA(R) (sodium phenylbutyrate)

(NASDAQ:ZVRA), MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients OLPRUVA offers the established efficacy and safety of sodium phenylbutyrate in a novel and convenient formulation for the

Aveanna Healthcare Announces Successful Debt Refinancing

(NASDAQ:AVAH), ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0 million in incremental first

[Latest] Global Beetroot Powder Market Size/Share Worth USD 640.5 Million by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Beetroot Powder Market Size, Trends and Insights By Product (Conventional, Organic), By Application (Food & Beverage, Nutraceuticals & Dietary Supplements, Cosmetics & Personal Care, Others), By Distribution Channel (Online, Offline), and By Region – Global Industry

Bowman Selected for Port of Houston Container Terminal Redevelopment Project

(NasdaqGM:BWMN), RESTON, Va., Sept. 18, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, has been awarded a contract to provide planning and design services relating to the redevelopment of the West End Container Yard at Barbours Cut Terminal in the Port of Houston. The selection

Scroll to Top